Ultragenyx Pharmaceutical Inc. (RARE)

NMS – Real vaqt narxi. Valyuta: USD

26.84

+0.54 (2.05%)

Yopilishda: May 12, 2026, 4:00 PM EDT

13.05.2026

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

07.05.2026

Rare disease families find roadmap to drug development at bootcamps

Rare disease families are increasingly driving research efforts to find treatments for their children. Ultragenyx's Rare Bootcamp gives advocates a roadmap for navigating drug development.

06.05.2026

Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference

NOVATO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Howard Horn, the company's Chief Financial Officer and Executive Vice President and Joshua Higa, Chief of Staff and Vice President of investor relations, will participate in a fireside at Bank of America's 2026 Healthcare Conference on Tuesday, May 12, 2026, at 2:20 PM PT.

06.05.2026

RARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal Effect

Ultragenyx posts a wider-than-expected Q1 loss as Crysvita sales fall on seasonal effects, while Evkeeza and Dojolvi revenue growth partially offset declines.

06.05.2026

Ultragenyx Pharmaceutical Inc. (RARE) Q1 2026 Earnings Call Transcript

05.05.2026

Ultragenyx (RARE) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

05.05.2026

Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates

Ultragenyx (RARE) came out with a quarterly loss of $1.84 per share versus the Zacks Consensus Estimate of a loss of $1.55. This compares to a loss of $1.57 per share a year ago.

Videolar

No Data

There is no data to display

Reytinglar oshishi / pasayishi

Ticker	Tashkilot	Reyting o‘zgarishi	Maqsadli narx	Sana
RARE	Wells Fargo	Overweight	undefined >> $65	October 20th 2025
RARE	H.C. Wainwright	Buy	undefined >> $80	July 28th 2025

Press-relizlar

06.05.2026

Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference

05.05.2026

Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update

First quarter total revenue of $136 million, Crysvita® revenue of $93 million and Dojolvi® revenue of $18 million

24.04.2026

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 36,447 restricted stock units of the company's common stock to 12 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of April 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

08.04.2026

RARE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - April 8, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ultragenyx Pharmaceutical Inc ("Ultragenyx" or the "Company") (NASDAQ: RARE) and reminds investors of the April 6, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Ultragenyx Pharmaceutical Inc. (RARE)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Ultragenyx Pharmaceutical Inc. (RARE)

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Rare disease families find roadmap to drug development at bootcamps

Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference

RARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal Effect

Ultragenyx Pharmaceutical Inc. (RARE) Q1 2026 Earnings Call Transcript

Ultragenyx (RARE) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference

Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RARE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Rare disease families find roadmap to drug development at bootcamps

Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference

RARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal Effect

Ultragenyx Pharmaceutical Inc. (RARE) Q1 2026 Earnings Call Transcript

Ultragenyx (RARE) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference

Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RARE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026

Search stocks

Ultragenyx Pharmaceutical Inc. (RARE)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Ultragenyx Pharmaceutical Inc. (RARE)

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Rare disease families find roadmap to drug development at bootcamps

Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference

RARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal Effect

Ultragenyx Pharmaceutical Inc. (RARE) Q1 2026 Earnings Call Transcript

Ultragenyx (RARE) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference

Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RARE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Rare disease families find roadmap to drug development at bootcamps

Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference

RARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal Effect

Ultragenyx Pharmaceutical Inc. (RARE) Q1 2026 Earnings Call Transcript

Ultragenyx (RARE) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference

Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RARE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026